Therapeutic factors, such as recombinant activated factor VII and plasma-derived activated prothrombin complex, are used for the treatment of hemophilia A patients with inhibitors, and the second generation therapeutic factors for hemophilia A patients with inhibitors are also currently under development. This evidence concerns the gene F7 and hemophilia A.